Search results: Sage Journals

Restricted accessResearch articleFirst published October, 2019

The Orphan Drug Act: An Appropriate Approval Pathway for Treatments of Rare Diseases?

Michael Gabay

Hospital Pharmacy

Restricted accessResearch articleFirst published January, 1997

The United States Orphan Drug ACT: Challenges and Success

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 1996

Orphan Drug Development Update

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published April, 1999

Orphan Drugs: The United States Experience

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 1998

Orphan Drug Development — International Program and Study Design Issues

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 1998

Designing Clinical Trials to Study Rare Disease Treatment

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 2010

The National Organization for Rare Disorders (NORD)

Stefanie Putkowski

NASN School Nurse

Restricted accessResearch articleFirst published November, 2009

US regulatory framework for rare plasma protein diseases

Mark Weinstein, Nisha Jain

Pharmaceuticals Policy and Law

Restricted accessOtherFirst published January, 2000

The Orphan Drug Act: Provisions and Considerations

Carson R. Reider

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published September, 2022

A catalyst for change? Orphan drugs and the case of C atalyst v. Becerra

Paul A Braier

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Restricted accessResearch articleFirst published October, 2019

The Orphan Drug Act: An Appropriate Approval Pathway for Treatments of Rare Diseases?

Michael Gabay

Hospital Pharmacy

Restricted accessResearch articleFirst published January, 1997

The United States Orphan Drug ACT: Challenges and Success

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 1996

Orphan Drug Development Update

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published April, 1999

Orphan Drugs: The United States Experience

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 1998

Orphan Drug Development — International Program and Study Design Issues

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 1998

Designing Clinical Trials to Study Rare Disease Treatment

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 2010

The National Organization for Rare Disorders (NORD)

Stefanie Putkowski

NASN School Nurse

Restricted accessResearch articleFirst published November, 2009

US regulatory framework for rare plasma protein diseases

Mark Weinstein, Nisha Jain

Pharmaceuticals Policy and Law

Restricted accessOtherFirst published January, 2000

The Orphan Drug Act: Provisions and Considerations

Carson R. Reider

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published September, 2022

A catalyst for change? Orphan drugs and the case of C atalyst v. Becerra

Paul A Braier

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector